Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2 Stomach Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Colorectal Neoplasms 1 Advanced Non-Small Cell Lung Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

Bevacizumab 187 Fluorouracil 150 Leucovorin 135 Cetuximab 127 Irinotecan 114 Oxaliplatin 108 pembrolizumab 97 Capecitabine 82 IFL protocol 53 Panitumumab 43 Nivolumab 43 regorafenib 42 Folfox protocol 39 Gemcitabine 30 trifluridine tipiracil drug combination 27 Cisplatin 25 Carboplatin 25 atezolizumab 23 Pemetrexed 21 Paclitaxel 20 Drug Therapy 20 130-nm albumin-bound paclitaxel 17 Trastuzumab 14 encorafenib 13 Trifluridine 13 Ipilimumab 13 HMPL-013 13 tislelizumab 12 spartalizumab 11 Docetaxel 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colorectal Neoplasms × quemliclustat × Clear all

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡